Antisense oligonucleotides targeted against glucocorticoid receptor reduce hepatic glucose production and ameliorate hyperglycemia in diabetic mice.
Abstract Specific blockade of glucocorticoid receptor (GCCR) action in the liver without affecting the hypothalamus-pituitary-adrenal axis could be a novel pharmaceutical approach to treat type 2 diabetes. In the present study, we applied an antisense oligonucleotide (ASO) against GCCR (ASO-GCCR) to reduce the expression of liver GCCR and examined its impact on the diabetic syndrome in ob / ob and db / db mice. A 3-week treatment regimen of ASO-GCCR (25 mg/kg IP, twice per week) markedly reduced liver GCCR messenger RNA and protein expression with no alteration of GCCR messenger RNA expression in the hypothalamus, pituitary, or adrenal gland. The ASO-GCCR treatment lowered blood glucose levels by 45% and 23% in ob / ob and db / db mice, respectively, compared with those observed in the control group. The ASO-GCCR-treated mice also showed significant enhancement of insulin-mediated inhibition of hepatic glucose production during a euglycemic-hyperinsulinemic clamp as well as marked reduction of phosphoenolpyruvate carboxykinase and glucose 6-phosphatase activity compared with control mice. The ASO-GCCR treatment did not change peripheral insulin sensitivity during the clamp. The ob / ob mice treated with ASO-GCCR had no significant difference in the plasma corticosterone and corticotropin levels compared with control mice. Lean mice receiving a similar treatment regimen of ASO-GCCR exhibited no change in blood glucose levels, oral glucose tolerance tests, or insulin tolerance tests. Our results demonstrate that selective inhibition of GCCR expression in the liver by the ASO-GCCR treatment reduced hepatic glucose production and improved blood glucose control under diabetic conditions.
Liang
Yin
Y
Endocrine Therapeutic and Metabolic Disorders, Johnson & Johnson Pharmaceutical Research & Development, LLC Raritan, NJ 08869, USA. yliang@prdus.jnj.com
Osborne
Melville C
MC
Monia
Brett P
BP
Bhanot
Sanjay
S
Watts
Lynnetta M
LM
She
Pengxiang
P
DeCarlo
Stephanie O
SO
Chen
Xiaoli
X
Demarest
Keith
K
D000818:Animals; D015153:Blotting, Western; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000378:metabolism*; D005260:Female; D005943:Gluconeogenesis / Q000187:drug effects*; D005951:Glucose Tolerance Test; D006943:Hyperglycemia / Q000517:prevention & control*; D008099:Liver / Q000378:metabolism*; D051379:Mice; D016376:Oligonucleotides, Antisense / Q000494:pharmacology*; D011965:Receptors, Glucocorticoid / Q000187:drug effects*
D016376:Oligonucleotides, Antisense; D011965:Receptors, Glucocorticoid